Target
KRAS G12C/D
3 abstracts
Abstract
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Columbia University Irving Medical Center, New York, NY, USA, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?Org: BC Cancer Agency Vancouver Island Centre, Guardant Health Inc., Duke University Medical Center, Guardant Health, Inc., The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.Org: Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Sixth Affiliated Hospital, SYSU, Guangzhou, China, The Sixth Affiliated hospital, Sun Yat-sen University, Guangzhou, China, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Third Affiliated Hospital of Kunming Medical University, Kunming, China, Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China, Department of Tumor Chemotherapy, Anhui Provincial Hospital, Hefei, China, Department of Oncology, The First Affiliated Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, China,